US regulators have warned startups in the emerging field of ‘molecular farming’ that expressing animal proteins such as casein in genetically engineered plants will require strict allergen management protocols.
Cultivated meat is edging closer to commercialization in the US as GOOD Meat becomes the second startup to secure a ‘no questions’ letter from the FDA affirming the safety of its process for growing chicken from cells, outside of the animal.
The letter grants GRAS (generally recognized as safe) status to Upside’s cultivated chicken product, paving the way for a market launch in the US.
But the startup needs to get regulatory approval before it can sell its cell-cultured salmon to US consumers.
Here Shmuel Rausnitz writes about his concerns relating to the FDA and foodtech entrepreneur’s tendency to oversimplify consumer demands and needs across demographics.
The US Food and Drug Administration (FDA) has come under fire for not providing more guidelines to food tech companies on what is and what is not allowed.
While it was a positive first step that the FDA addressing the space, how it will play out is still uncertain as participants debated who should regulate the products, what it should be called, and how its safety will be determined.
Monsanto’s lawsuit, cannabis legalization in New Zealand, and continued drama around GMO-labeling are some of the stories covered in this week’s Industry-in-Brief.
This week’s news-in-brief covers the launch of a new crop-spraying drone, a $20m commitment by New Zealand to combat agricultural emissions, and agribusiness PE fund Arlon leads sugar business M&A.
According to the United States Food and Drug Administration (FDA), each year roughly 48 million get sick, 128,000 require hospitalization, and 3,000 lose their lives
Smoke & mirrors, not worth the extra cost: 50 US farmers speak out on carbon markets